We are live on ! Find out more
IDXG

Interpace Biosciences, Inc. Common Stock
IDXG

Delisted

IDXG was delisted on the 24th of February, 2021.

Back to rankings

29 hedge funds and large institutions have $37.1M invested in Interpace Biosciences, Inc. Common Stock in 2013 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 11 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less capital invested

Capital invested by funds: $37.9M → $37.1M (-$780K)

18% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 11

34% less funds holding

Funds holding: 44 → 29 (-15)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 15

Holders
29
Holders Change
-15
Holders Change %
-34.09%
% of All Funds
0.94%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
9
Reduced
11
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
HA
Heartland Advisors
Wisconsin
+$1.08M
2
KCM
Kennedy Capital Management
Missouri
+$527K
3
SKK
Shepherd Kaplan Krochuk
Massachusetts
+$33.5K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$22K
5
BFA
BlackRock Fund Advisors
California
+$10.5K

Top Sellers

1
RA
Royce & Associates
New York
-$1.08M
2
KSC
Kendall Square Capital
California
-$669K
3
Northern Trust
Northern Trust
Illinois
-$354K
4
PP
Paloma Partners
Connecticut
-$205K
5
CI
Cowen Inc
New York
-$163K
Name Holding Trade Value Shares
Change 		Change in
Stake
GT
26
Glenmede Trust
Pennsylvania
$9K – – –
NFA
27
Nationwide Fund Advisors
Ohio
$8K -$21.1K -44 -73%
TRCT
28
Tower Research Capital (TRC)
New York
$6K -$22.5K -47 -78%
Manulife (Manufacturers Life Insurance)
29
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$5 – – –
PP
30
Paloma Partners
Connecticut
– -$205K -436 Closed
CI
31
Cowen Inc
New York
– -$163K -346 Closed
Bank of America
32
Bank of America
North Carolina
– -$106K -226 Closed
CS
33
Credit Suisse
Switzerland
– -$95K -203 Closed
Morgan Stanley
34
Morgan Stanley
New York
– -$82K -174 Closed
JP Morgan Chase
35
JP Morgan Chase
New York
– -$72K -154 Closed
Citadel Advisors
36
Citadel Advisors
Florida
– -$68K -144 Closed
ARTA
37
A.R.T. Advisors
New York
– -$52K -111 Closed
Barclays
38
Barclays
United Kingdom
– -$51K -108 Closed
BIP
39
Brandes Investment Partners
California
– -$51K -108 Closed
U
40
UBS
Switzerland
– -$35K -75 Closed
AIG
41
American International Group
New York
– -$32.4K -69 Closed
Royal Bank of Canada
42
Royal Bank of Canada
Ontario, Canada
– -$9K -19 Closed
TCIM
43
TIAA CREF Investment Management
New York
– -$5K -11 Closed
1
2

IDXG Hedge Fund Activity: Q3 2013 in Review

29 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q3 2013, worth a combined $37.1M — down 2.1% from $37.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of IDXG and 0 opened new positions — a net loss of 15 holders — while 11 trimmed existing stakes and 9 added.

The largest buyer was Heartland Advisors, adding an estimated $1.08M. The largest seller was Royce & Associates, cutting an estimated $1.08M.

  • 29 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q3 2013, down from 44 in Q2 2013.
  • Funds reported $37.1M of Interpace Biosciences, Inc. Common Stock stock for Q3 2013, down 2.1% quarter-over-quarter.
  • 0 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q3 2013 and 15 closed out, a net change of -15 holders.
  • The largest Interpace Biosciences, Inc. Common Stock buyer in Q3 2013 was Heartland Advisors, an estimated $1.08M added.
  • The largest Interpace Biosciences, Inc. Common Stock seller in Q3 2013 was Royce & Associates, an estimated $1.08M sold.

Based on aggregated 13F filings for Q3 2013.